Best Grants for Cancer Nonprofits in Delaware

The Melanoma Research Resident and Fellowship Grant offers $10,000 to support early-career residents and fellows in conducting clinical or laboratory research focused on melanoma. This grant encourages innovative approaches to understanding prevention, detection, and treatment of melanoma, including special emphasis on ocular melanoma. Eligible candidates must have a qualified mentor and conduct research at a U.S. institution. This initiative aims to enhance the landscape of melanoma research and foster the next generation of researchers.

The External Collaborative Research Grants by Boehringer Ingelheim support academic and clinical scientists in proposing research studies. These grants facilitate collaboration with Boehringer Ingelheim, which may provide intellectual and financial support. Applicants must assume full responsibility for their research while complying with regulatory standards. The funding should cover research costs, excluding salary support for the collaborative partner. Interested investigators must apply online for consideration.

Amgen is a leading biotechnology company dedicated to advancing medicine through Independent Medical Education (IME). It funds accredited educational programs that empower healthcare providers to enhance patient care. IME funding supports critical areas such as oncology, bone health, cardiovascular education, and more. Amgen's commitment ensures that these educational activities remain unbiased and compliant with applicable guidelines, fostering innovation and improved health outcomes for patients worldwide.

The U.S. Healthcare Donations program by Amgen aims to support not-for-profit organizations in the healthcare sector. As a leading biotechnology company, Amgen provides funding for initiatives that improve science, technology, education, and public awareness on medical conditions. Organizations eligible for funding must be tax-exempt entities, focusing on genuine philanthropic efforts that align with Amgen's mission to enhance health outcomes and reduce the burden of diseases.

The CSS Dharm V. Singh Carcinogenesis Graduate Student Endowment Award, established by the Society of Toxicology, encourages graduate students to submit abstracts for competition. The award, which includes a $750 cash prize for the first-place winner, aims to promote research in carcinogenesis. Additional prizes of $500 and $350 are awarded for second and third place. This initiative strengthens the commitment to diversity and inclusion in scientific research, fostering a healthier and safer world.

The Research Scholar Grants (RSG) by the American Cancer Society support independent researchers engaged in cancer-related studies. Eligible applicants must be affiliated with US academic institutions and have been appointed as independent faculty for less than ten years. Grants provide funding up to $215,000 annually for direct costs and allow for 10% indirect costs, with project durations of up to four years, fostering innovative cancer research across various priority areas.

The ACS Professor Award, presented by the American Cancer Society, recognizes full professors who have significantly advanced cancer research. This honorific award aims to support innovative pursuits in cancer research with a budget of up to $80,000 per year for five years. Applicants are expected to demonstrate impactful contributions and leadership in the field, along with a commitment to mentorship and community engagement. The award highlights the importance of ongoing advocacy and research in improving cancer treatment and prevention.

About Alex’s Lemonade Stand Foundation

Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4- year-old Alexandra “Alex” Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. Her spirit and determination inspired others to support her cause, and when she passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a national fundraising movement. Today, ALSF is one of the leading funders of pediatric cancer research in the U.S. and Canada, funding research projects and providing programs to families affected by childhood cancer. ALSF is one of the only childhood cancer research organizations that has been given the NCI peer-reviewed funder designation for rigorous selection of research grants. The mission of ALSF is to change the lives of children with cancer through funding impactful research, raising awareness, supporting families, and empowering everyone to help cure childhood cancer.

Bio-Therapeutic Impact Award

The Bio-Therapeutic Impact Award accelerates the development of clinical trials for promising biologic approaches to treating childhood cancer. These approaches include, but are not limited to, immunotherapy, gene therapy and small molecules. The award, intended for investigators who are initiating clinical trials, totals the maximum of $1.8 million awarded over three years.

The Damon Runyon Physician-Scientist Training Award aims to address the shortage of physician-scientists by supporting U.S. Specialty Board eligible physicians in cancer research. This award provides funding for up to four years, enabling awardees to dedicate 80% of their time to research while maintaining clinical skills. The program seeks to eliminate financial barriers, allowing talented clinicians to transform into leading researchers capable of advancing cancer treatment and prevention.

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.

The Scott R. MacKenzie Foundation offers grants to support innovative genetic research aimed at advancing cures for diseases like cancer, diabetes, lung, and heart diseases. Only U.S.-based tax-exempt organizations with over five years of operation can apply. The Foundation emphasizes collaboration among research entities to enhance genome sequencing and disease detection. By funding these initiatives, they aim to foster awareness and progress in genetic research for future generations.

The McKesson Foundation Grant provides funding above $25,000 to support health equity initiatives across North America. Founded in 1943, its mission focuses on removing barriers to quality healthcare for vulnerable communities. The foundation prioritizes projects that align with strategic pillars: reducing cancer burdens, preparing the healthcare workforce, and enhancing crisis response. Eligible organizations include national and local nonprofits. Funding is limited to specific regions and assessed based on demonstrated need and expected impact.

The Elsa U. Pardee Foundation has been a pioneer in cancer research funding since 1944, providing over $110 million to more than 300 institutions across the U.S. It supports innovative approaches by both new and established researchers, ensuring diverse ideas receive necessary funding. Additionally, the Foundation addresses immediate financial needs for cancer patients, allocating about one-third of its grants to assist those in need. This dual focus on research and patient support distinguishes the Foundation in the fight against cancer.

The Barney Family Foundation Grant focuses on improving early education and advancing medical research, particularly in cancer and Alzheimer’s. It supports organizations that demonstrate a clear plan to enhance children's life experiences and educational opportunities for those in grades K-8. Grants typically range from $5,000 to $50,000, prioritizing established entities while welcoming startups. Eligible applicants must have 501(c)(3) status, and the Foundation does not fund individual requests or political activities.

The Brees Dream Foundation Grant aims to enhance the lives of cancer patients while providing essential care, education, and opportunities for children and families in need. With the support of generous donors and partners, the Foundation is dedicated to advancing cancer research and offering vital resources to those facing challenges. This commitment reflects a profound dedication to improving quality of life and fostering hope in communities.

The Pershing Square Sohn Cancer Prize is awarded to early-career scientists in the New York area who are pursuing innovative cancer research. Established by the Pershing Square Foundation in partnership with The Sohn Conference Foundation, the prize offers $250,000 annually for up to three years. With a commitment of over $49 million since 2013, the Alliance aims to accelerate cancer cures by fostering collaborations between academia and industry, providing a unique network and access to vital resources for groundbreaking research.

Sanofi Philanthropic Donations support non-profit organizations aligned with Health Equity, STEM Education Equity, and Local Communities. Applications are accepted year-round, with a review process of 8 to 16 weeks. The initiative focuses on improving healthcare access, fostering innovation, and addressing social determinants of health. Sanofi emphasizes collaboration and sustainable solutions, advocating for equal opportunities in health and education, and nurturing future talent to tackle medical challenges.

The Prevent Cancer Foundation is launching a $100,000 community grant program for 2024-2026, focusing on patient navigation for cancer prevention and early detection. Community-based organizations can apply for funding over two years to enhance their efforts. Priority will be given to applicants demonstrating best practices, established community partnerships, and initiatives that address health disparities. Note that the application cycle opens in 2026, emphasizing the importance of proactive health measures.

Exelixis Grants & Giving focuses on impactful charitable contributions, supporting non-profit organizations in community support, healthcare-related initiatives, independent patient assistance, medical education, and sponsorships. Their aim is to enhance oncology care, particularly for renal cell carcinoma and other cancer types, while ensuring proposals are submitted within specified timelines. Exelixis partners with organizations dedicated to improving patient outcomes and community health, demonstrating their commitment to making a difference beyond medicine.

The ASTRO Medical Student Fellowship Award for Underrepresented Populations aims to enhance diversity in radiation oncology by supporting medical students from underrepresented backgrounds. Awardees receive a $6,000 package, including a stipend for an eight-week training program, funds for travel expenses, and mentorship opportunities. This initiative is part of ASTRO's broader mission to advance patient care and professional development in the field of radiation oncology, fostering an inclusive environment in medical education.

The Myelodysplastic Syndromes (MDS) Research Fund Grant, established by the Vera and Joseph Dresner Foundation, aims to enhance research and treatment of MDS and related blood disorders. This fund supports innovative projects addressing etiology, biology, genetics, prognosis, treatment, symptom management, and quality of life. It offers up to $125,000 for Early Career Awards and $250,000 for Established Investigator Awards, facilitating significant advancements in the field.

The National Cancer Institute (NCI) invites applications for studies on mechanisms by which bariatric surgery influences cancer risk. This funding opportunity encourages exploration beyond short-term outcomes like weight loss and diabetes. The goal is to support innovative proof of concept studies, emphasizing feasibility without prior development in the literature. Unpublished data is not allowed, but references from preprints with a DOI are acceptable. Deadlines for applications span from February 2025 to November 2027.

The NIH is inviting applications for interventions aimed at enhancing cancer screening and preventive services in underserved populations. This initiative focuses on addressing barriers to healthcare access and promoting timely follow-up on abnormal findings. Collaborations with community partners are encouraged to foster effective outreach. The program particularly seeks to engage patients, clinicians, and healthcare settings in improving health equity and outcomes in cancer prevention.

The Emerging Global Leader Award (K43) offers essential research support and protected time for early career scientists in low- and middle-income countries. This program, aligned with NIH's clinical trials policy, aims to cultivate independent research careers by providing mentorship and funding over three to five years. Eligible candidates must hold a junior faculty position at an accredited LMIC institution, fostering the growth of research capacity in their regions.

The Fogarty Emerging Global Leader Award supports early career research scientists from low- or middle-income countries (LMIC) by providing research funding and mentored career development for three to five years. This program encourages LMIC scientists in health-related fields to develop projects aligned with their country's health priorities, fostering independent research careers within their institutions. Applications are welcomed from junior faculty members, enhancing global health research and capacity in LMICs.

The Extramural Discovery Science Accelerator Award supports the commercialization of ongoing cancer research projects, focusing on experiments that facilitate technology validation and de-risking. Applications are accepted on a rolling basis, with a budget of up to $75,000 for one year. This award encourages independent investigators at any career stage to advance their technologies, with a strong emphasis on commercial viability and collaboration within a learning community.

The Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) aims to enhance cancer treatment by integrating imaging and liquid biopsy assays. This initiative, led by the National Cancer Institute (NCI), encourages grant applications focused on assessing therapy responses and resistance emergence in patients. Key deadlines for submissions span from February 2025 to January 2028, providing ample opportunities for researchers to contribute to this vital area of cancer research.